Muhammad Umer

Global Kinetics

Global Kinetics Pty Ltd (GK) is committed to improving the lives of those with Parkinson's disease and other movement disorders, with advanced medical technologies. GK is on a trajectory to revolutionize the management of Parkinson's disease by enabling informed treatment decisions which are based on continuous and objective measurement of patients' key movement symptoms in everyday environments. Its lead product, the Parkinson's KinetiGraph®(PKG® or Personal KinetiGraph® in the US), has been developed by neurologists at the world-renowned Florey Institute of Neuroscience in Melbourne, Australia. The PKG® enables the precise monitoring, quantification and reporting of movement patterns of neurological diseases including bradykinesia, dyskinesia, tremor and immobility. Our PKG technology: • Technically de-risked and established in market – over 6,000,000 hours of continuous Parkinson's monitoring delivered to date, representing more than 25,000 patient PKGs • Changes clinical decisions more than 50% of the time • Boasts significant key opinion leader support • Is underpinned by robust clinical validation and regulatory clearance through FDA 510(k) in the USA, CE mark in Europe, TGA Class IIA ARTG 236583 listed The PKG® system is being used in clinics across the U.S., Europe and Asia Pacific, enabling better clinical outcomes and reducing health care costs across the Parkinson's disease continuum. GK continues to pursue partnerships with major pharmaceutical and medical technology companies to help measure the efficacy of new and advanced therapies for one of the world's most widespread movement disorders. For further information, please visit our website, www.pkgcare.com